MDCO


The Medicines Company (MDCO): How Much Vabomere Worth?

This morning, The Medicines Company (NASDAQ:MDCO) reported that the FDA approved its urinary tract infection treatment Vabomere, a move the drug maker hopes will bolster …

Chardan Bullish on The Medicines Company (MDCO); Reiterates $85 Price Target

In a research report issued Wednesday, Chardan analyst Gbola Amusa reiterated a Buy rating on shares of The Medicines Company (NASDAQ:MDCO) with a price …

Oppenheimer Comments on The Medicines Company (MDCO) Following FDA Approval for VABOMERE

The Medicines Company’s Vabomere – A Solid Option for CarbapenemResistant cUTIs: Oppenheimer

The Medicines Company (MDCO) Wins FDA Approval for cUTI Treatment in Adults; Shares Climb

The Medicines Company (NASDAQ:MDCO) announced that the U.S.

The Medicines Company (MDCO): Inclisiran Shows Momentum on Longer-Term Data, Oppenheimer Weighs in

Yesterday, at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, The Medicines Company (NASDAQ:MDCO) unveiled positive one-year data from the 501-patient …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts